Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-669/ECHO-304
2024-512015-47-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Jan 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, epacadostat, cetuximab, cisplatin, carboplatin and 1 more in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Incyte. Primary endpoint: Objective Response Rate (ORR). Started Jan 2018; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-512015-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512015-47-00.